We are live on ! Find out more
MLTX icon

MoonLake Immunotherapeutics
MLTX

83 hedge funds and large institutions have $2.86B invested in MoonLake Immunotherapeutics in 2023 Q2 according to their latest regulatory filings, with 47 funds opening new positions, 25 increasing their positions, 8 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

571% more first-time investments, than exits

New positions opened: 47 | Existing positions closed: 7

400% more funds holding in top 10

Funds holding in top 10: 2 → 10 (+8)

239% more capital invested

Capital invested by funds: $843M → $2.86B (+$2.02B)

213% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 8

93% more funds holding

Funds holding: 43 → 83 (+40)

27.75% more ownership

Funds ownership: 100.69% → 128.44% (+28%)

Holders
83
Holders Change
+40
Holders Change %
+93.02%
% of All Funds
1.3%
Holding in Top 10
10
Holding in Top 10 Change
+8
Holding in Top 10 Change %
+400%
% of All Funds
0.16%
New
47
Increased
25
Reduced
8
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$78.1M
2
ACA
Avoro Capital Advisors
New York
+$46.4M
3
CAM
Cormorant Asset Management
Massachusetts
+$33.6M
4
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
+$30.9M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$29.9M

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$24.3M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$7.98M
3
GPP
Great Point Partners
Connecticut
-$5.95M
4
Axa
Axa
France
-$3.94M
5
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$3.45M
Name Holding Trade Value Shares
Change 		Change in
Stake
Marshall Wace
51
Marshall Wace
United Kingdom
$2.98M +$1.57M +58,383 New
Alyeska Investment Group
52
Alyeska Investment Group
Illinois
$2.92M +$1.54M +57,347 New
VCIM
53
Velan Capital Investment Management
Georgia
$2.82M +$858K +31,900 +136%
MIM
54
Monashee Investment Management
Massachusetts
$2.55M +$1.35M +50,000 New
WP
55
Woodline Partners
California
$2.52M +$1.33M +49,479 New
Bank of America
56
Bank of America
North Carolina
$2.18M +$871K +32,377 +315%
Squarepoint
57
Squarepoint
New York
$2.11M +$1.11M +41,431 New
E
58
Ergoteles
New York
$1.97M +$1.04M +38,617 New
VOYA Investment Management
59
VOYA Investment Management
Georgia
$1.79M +$944K +35,090 New
Geode Capital Management
60
Geode Capital Management
Massachusetts
$1.63M +$400K +14,859 +87%
TCM
61
TimesSquare Capital Management
New York
$1.53M +$807K +30,000 New
Victory Capital Management
62
Victory Capital Management
Texas
$1.07M +$564K +20,950 New
EI
63
EAM Investors
California
$1.07M +$563K +20,917 New
Royal Bank of Canada
64
Royal Bank of Canada
Ontario, Canada
$1.03M +$526K +19,540 +2,979%
SFG
65
SVB Financial Group
Texas
$825K – – –
Renaissance Technologies
66
Renaissance Technologies
New York
$791K -$194K -7,200 -32%
GGHC
67
Gilder Gagnon Howe & Co
New York
$767K +$405K +15,047 New
Tudor Investment Corp
68
Tudor Investment Corp
Connecticut
$691K +$365K +13,549 New
ACH
69
ArrowMark Colorado Holdings
Colorado
$510K +$269K +10,000 New
SC
70
Shay Capital
New York
$485K +$256K +9,500 New
Connor, Clark & Lunn Investment Management (CC&L)
71
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$480K +$253K +9,421 New
WS
72
Wedbush Securities
California
$351K +$185K +6,890 New
LPL Financial
73
LPL Financial
California
$311K +$164K +6,095 New
Envestnet Asset Management
74
Envestnet Asset Management
Illinois
$260K +$137K +5,098 New
PNC Financial Services Group
75
PNC Financial Services Group
Pennsylvania
$221K +$116K +4,327 New
1 2
3
4

MLTX Hedge Fund Activity: Q2 2023 in Review

83 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in MoonLake Immunotherapeutics (MLTX) for Q2 2023, worth a combined $2.86B — up 239% from $843M a quarter earlier.

Buyers outnumbered sellers: 47 funds opened new MLTX positions and 7 closed out — a net gain of 40 holders — while 25 added to existing stakes and 8 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $78.1M. The largest seller was Citadel Advisors, cutting an estimated $24.3M.

  • 83 institutional investors held MoonLake Immunotherapeutics (MLTX) as of Q2 2023, up from 43 in Q1 2023.
  • Funds reported $2.86B of MoonLake Immunotherapeutics stock for Q2 2023, up 239% quarter-over-quarter.
  • 47 funds opened new MoonLake Immunotherapeutics positions in Q2 2023 and 7 closed out, a net change of +40 holders.
  • The largest MoonLake Immunotherapeutics buyer in Q2 2023 was Fidelity Investments, an estimated $78.1M added.
  • The largest MoonLake Immunotherapeutics seller in Q2 2023 was Citadel Advisors, an estimated $24.3M sold.

Based on aggregated 13F filings for Q2 2023.